Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623zct

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 4	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 5	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 6	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 7	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 8	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS 9	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 10	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS 11	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS 12	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 13	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 14	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:59:30 ON 22 SEP 2004

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:59:39 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2004 HIGHEST RN 748739-98-2
DICTIONARY FILE UPDATES: 20 SEP 2004 HIGHEST RN 748739-98-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\HONGS DOG 09960634.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 17 18 19 20
ring nodes :
11 12 13 14 15 16
chain bonds :
1-2 1-3 1-11 3-4 3-5 5-6 6-7 6-8 8-9 9-10 10-17 10-18 18-19 19-20
ring bonds :
11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
1-2 1-3 3-5 6-7 10-17 10-18 18-19 19-20
exact bonds :
1-11 3-4 5-6 6-8 8-9 9-10
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS
19:CLASS 20:Atom

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR

10/960,634
UPDATE SEARCH 9/22/04
STN SEARCH TRANSCRIPT - DON'T REMOVE -



Structure attributes must be viewed using STN Express query preparation.

```
=> S L1
SAMPLE SEARCH INITIATED 09:00:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   9335 TO ITERATE

 10.7% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       180911 TO   192489
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 09:00:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 184803 TO ITERATE

 99.0% PROCESSED  182938 ITERATIONS                               7 ANSWERS

100.0% PROCESSED  184803 ITERATIONS                               7 ANSWERS
SEARCH TIME: 00.00.21

L3             7 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              155.84     156.05

FILE 'CAPLUS' ENTERED AT 09:00:35 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 22 Sep 2004 VOL 141 ISS 13

FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> S L3
L4             4 L3

=> D 1-4 IBIB ABS HITSTR
```

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:43054 CAPLUS
DOCUMENT NUMBER: 138:107007
TITLE: Preparation of 5-amino-4-hydroxypentanoic acid derivatives for treating Alzheimer's disease
INVENTOR(S): Hom, Roy; Mamo, Shumeye; Tung, Jay; Gailunas, Andrea; John, Varghese; Fang, Lawrence
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 113 pp., Cont.-in-part of U. S. Ser. No. 815,960.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

APPLICANTS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003013881	A1	20030116	US 2001-960634	20010921
US 2002019403	A1	20020214	US 2001-816876	20010323
US 2002022623	A1	20020221	US 2001-815960	20010323
US 6737420	B2	20040518		

PRIORITY APPLN. INFO.: US 2000-191528P P 20000323
US 2001-815960 A2 20010323
US 2001-816876 A2 20010323
OTHER SOURCE(S): MARPAT 138:107007

AB The invention is directed toward substituted hydroxyethylene compds. having the fragment -NHCHR1CH(OH)CH2CHR2CO- [R1 = alkyl, alkylthioalkyl, alkenyl, (hetero)aryl, (hetero)arylalkyl, heterocyclylalkyl, or heterocyclyl; R2 = H, alkyl, cycloalkylalkyl, or (hetero)aryl] for use in treating Alzheimer's disease and similar diseases. In an example, N-[(1S,2S,4R)-1-(3,5-difluorobenzyl)-4-(syn,syn)-(3,5-dimethoxycyclohexylcarbamoyl)-2-hydroxyhexyl]-N,N-dipropylisophathalamide was prepared by solution-based methodol.

IT **362480-29-3P 362480-32-8P 362480-38-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino(hydroxy)pentanoic acid derivs. for treating Alzheimer's disease)

RN 362480-29-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2S,4R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-4-methyl-5-[[2-(4-morpholinyl)ethyl]amino]-5-oxopentyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362480-32-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2S,4R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-4-methyl-5-oxo-5-[[(tetrahydro-2-furanyl)methyl]amino]pentyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362480-38-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2S,4R)-1-[(3,5-difluorophenyl)methyl]-5-[(2-furanylmethyl)amino]-2-hydroxy-4-methyl-5-oxopentyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:713293 CAPLUS
DOCUMENT NUMBER: 135:273220
TITLE: Preparation of hydroxyethylenes with peptide subunits for pharmaceutical use in the treatment of Alzheimer's disease
INVENTOR(S): Hom, Roy; Mamo, Shumeye; Tung, Jay; Gailunas, Andrea; John, Varghese; Fang, Larry
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

APPLICANTS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070672	A2	20010927	WO 2001-US9501	20010323
WO 2001070672	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1265849	A2	20021218	EP 2001-926424	20010323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003528071	T2	20030924	JP 2001-568884	20010323
PRIORITY APPLN. INFO.:			US 2000-191528P	P 20000323
			WO 2001-US9501	W 20010323

OTHER SOURCE(S): MARPAT 135:273220
AB Hydroxyethylenes, such as RNHCHR1CH(OH)CH2CHR2COBR3 [R = peptidyl group, acyl, etc.; R1 = alkyl, alkenyl, arylalkyl, etc.; R2 = H, alkyl, cycloalkyl, arylalkyl, etc.; BR3 = peptidyl group; B = O, NR4; R3 = alkyl, arylalkyl, etc.; R4 = H, alkyl, etc.], were prepared as agents for the treatment of Alzheimer's disease. Thus, BOC-L-Val-L-Met-NH-(S,S,S)-CH(CH2CHMe2)CH(OH)CH(CHMe2)CO-L-Ala-L-Glu-L-Phe-OH via a series of amide coupling reactions of the corresponding amino acids with the

hydroxyethylene moiety. The prepared hydroxyethylenes were tested for β-secretase inhibiting activity.

IT **362480-29-3P 362480-32-8P 362480-38-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxyethylenes with peptide subunits for pharmaceutical use in the treatment of Alzheimer's disease)

RN 362480-29-3 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2S,4R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-4-methyl-5-[[2-(4-morpholinyl)ethyl]amino]-5-oxopentyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362480-32-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2S,4R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-4-methyl-5-oxo-5-[[(tetrahydro-2-furanyl)methyl]amino]pentyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362480-38-4 CAPLUS
CN 1,3-Benzenedicarboxamide, N'-[(1S,2S,4R)-1-[(3,5-difluorophenyl)methyl]-5-[(2-furanylmethyl)amino]-2-hydroxy-4-methyl-5-oxopentyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:207292 CAPLUS
DOCUMENT NUMBER: 128:270871
TITLE: Preparation of azolyl dipeptide analogs as retroviral protease inhibitors
INVENTOR(S): Carr, Thomas Joseph; Demarsh, Peter Lawrence; Dreyer, Geoffrey Bainbridge; Fenwick, Ashley Edward
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: U.S., 42 pp., Cont. of U.S. Ser. No. 193.026, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733882	A	19980331	US 1995-396356	19950228
PRIORITY APPLN. INFO.:			US 1994-193026	19940117

OTHER SOURCE(S): MARPAT 128:270871
GI

4
CITED
IN
I.D.S.
FILED
25 JAN 2002

I



II



III



IV

AB The present invention provides compds., more particularly dipeptide analogs I [R1, R3 = independently (un)substituted Q, Q-C1-6 alkyl, Q-C2-6 alkenyl, Q-C2-6 alkynyl, C1-6 alkyl substituted by 1-5 F atoms; Q = H, C3-6 cycloalkyl, C5-6 cycloalkenyl, aryl, heterocyclyl; R2 = H, OH; R4 = R6NR11, CONR11CHR6R7; R5 = R6NR11, R10NR11; X = NR11, O, S; R7 = Q, Q-C1-6 alkyl, Q-C2-6 alkenyl; R8, R9 = independently H, OH, halo, NO2, acyl, CF3, aryl, etc.; R8R9 = fused C2-4 alkylene, aryl, heterocyclyl; R10 = A-(B)n; R11 = H, C1-4 alkyl; B = amino acid; A = H, (un)substituted aryl, heterocyclyl, aryl-W, heterocyclyl-W, phthaloyl, etc.; W = CO, O2C, NR11CO, SCO, NR11CS, SO2, NR11SO2, P(O)(OR22); R22 = H, C1-6 alkyl, Ph, phenyl-C1-4 alkyl; with provisos], or a pharmaceutically acceptable salt thereof, which bind to retroviral proteases. These compds. are inhibitors of retroviral proteases and are useful for treating diseases related to infection by retroviruses. Thus, cyclocondensation of protected valinal Z-Val-H (Z = PhCH2O2C) with ammonia and glyoxal gave imidazole II. Deprotection of II, followed by coupling with dipeptide isostere III, and final desilylation gave desired title compound IV as its HCl salt. The prepared compds., including IV, showed inhibition of HIV-1 protease with Ki = 1 nM to 5 μM, and inhibited infection of cells with the HIV virus with IC50 = 0.1 to 10 μM.

IT **149356-76-3P 149356-77-4P 149356-79-6P 149356-81-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolyl dipeptide analogs as retroviral protease inhibitors)

RN 149356-76-3 CAPLUS
CN Benzenehexanamide, δ-(benzoylamino)-γ-hydroxy-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149356-77-4 CAPLUS
CN Benzenehexanamide, γ-hydroxy-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-δ-[(4-methoxybenzoyl)amino]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149356-79-6 CAPLUS
CN Benzenehexanamide, γ-hydroxy-δ-[(4-hydroxybenzoyl)amino]-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149356-81-0 CAPLUS
CN Benzenehexanamide, γ-hydroxy-δ-[(2-hydroxybenzoyl)amino]-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



NOT IN RC DEF'N NO - REJ'N.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:517245 CAPLUS
DOCUMENT NUMBER: 119:117245
TITLE: Preparation of N-imidazolylalkyl-5-amino-4-hydroxyhexanamides and analogs as retroviral protease inhibitors
INVENTOR(S): Carr, Thomas Joseph; DeMarsh, Peter Lawrence; Penwick, Ashley Edward
PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9302057	A1	19930204	WO 1992-US6047	19920717
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KR, LU, NL, NO, PL, RO, RU, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9224129	A1	19930223	AU 1992-24129	19920717
CN 1071434	A	19930428	CN 1992-109761	19920717
ZA 9205360	A	19930614	ZA 1992-5360	19920717
EP 602069	A1	19940622	EP 1992-917238	19920717
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 07500577	T2	19950119	JP 1992-503016	19920717
ES 2068739	B1	19951101	ES 1993-107	19930121
ES 2068739	A1	19950416		

PRIORITY APPLN. INFO.: US 1991-731563 19910717
US 1992-870975 19920420
WO 1992-US6047 19920717

OTHER SOURCE(S): MARPAT 119:117245

AB R5CHR1CH(OH)CHR2CHR3R4 [I; R1, R3 = fluoroalkyl, cycloalk(en)yl(alkyl), aryl(alkyl), heterocyclyl(alkyl), etc.; R2 = H, OH; R4 = azolylamino, N-(azolylalkyl)carbamoyl; R5 = substituted amino] were prepared Thus, Me2CHCHRNH2 (R = imidazol-2-yl) (preparation given) was condensed with (2R, 4S, 5S)-PhCH2CH(NHCO2CMe3)CH(OR6)CH2CH(CH2Ph)COR7 (II; R6 = SiMe2CMe3, R7 = OH) to give, after deprotection, II (R6 = H, R7 = NHCHRCHMe2, R = imidazol-2-yl). I had Ki of 1 nM to 5 μM for inhibition of HIV-1 protease.

IT **149356-76-3P 149356-77-4P 149356-79-6P 149356-81-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as retroviral protease inhibitor)

RN 149356-76-3 CAPLUS
CN Benzenehexanamide, δ-(benzoylamino)-γ-hydroxy-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149356-77-4 CAPLUS
CN Benzenehexanamide, γ-hydroxy-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-δ-[(4-methoxybenzoyl)amino]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149356-79-6 CAPLUS
CN Benzenehexanamide, γ-hydroxy-δ-[(4-hydroxybenzoyl)amino]-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149356-81-0 CAPLUS
CN Benzenehexanamide, γ-hydroxy-δ-[(2-hydroxybenzoyl)amino]-N-[1-(1H-imidazol-2-yl)-2-methylpropyl]-α-(phenylmethyl)-, [αR-[N(S*),αR*,γS*,δS*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.48	175.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.80	-2.80

STN INTERNATIONAL LOGOFF AT 09:00:58 ON 22 SEP 2004